5-Fluoro-AET, also known as 5-fluoro-ñ-ethyltryptamine or by the code name PAL-545, is a substituted tryptamine derivative which acts as a serotoninâÂÂdopamine releasing agent (SDRA) and as an agonist of the serotonin 5-HT<sub>2A</sub> receptor.
Its values for monoamine release are 36.6nM for serotonin, 5,334nM for norepinephrine, and 150nM for dopamine in rat brain synaptosomes. Its at the serotonin 5-HT<sub>2A</sub> receptor is 246nM and its at the receptor is 87%.
Several close analogues of 5-fluoro-ñET, including 5-fluoro-ñMT and 5-chloro-ñMT, are known to be potent monoamine oxidase inhibitors (MAOIs), specifically of monoamine oxidase A (MAO-A). However, ñ-ethyltryptamine (ñET) is a very weak MAOI. 5-Fluoro-ñET has also more recently been assessed, and in contrast to ñET, but similarly to drugs like 5-fluoro-ñET, was found to be a potent MAOI, with an of 2,480nM. Potent monoamine oxidase inhibition by monoamine releasing agents (MRAs) has been associated with dangerous and sometimes fatal toxicity in humans.
Analogues of 5-fluoro-AET include ñ-ethyltryptamine (AET), 5-fluorotryptamine, 4-methyl-AET, 5-chloro-AET, 5-chloro-AMT, 5-fluoro-AMT, 5-fluoro-DMT, bretisilocin (5-fluoro-MET), 5-MeO-AET, 6-fluoro-AMT, 7-chloro-AMT, 7-methyl-DMT, and 7-methyl-AET, among others.
5-Fluoro-AET is not an explicitly nor implicitly controlled substance in Canada as of 2025.
5-Fluoro-AET is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.